Melet

Pheniramine maleate and tetryzoline hydrochloride, the active ingredients in Melet, are an antihistamine and an alpha‑adrenergic agonist presented as eye drops for ocular use. They treat allergic conjunctivitis, eye itching, and redness in patients with ocular allergy.

GNH USA supplies Melet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melet acts on ocular allergic pathways to relieve symptoms of eye inflammation and irritation.

Allergic conjunctivitis: reduces itching, redness and swelling of the conjunctiva. Eye itching: alleviates pruritus caused by allergic eye disease. Conjunctival hyperemia: diminishes vascular redness and improves visual comfort.

Common Side Effects: - Stinging or burning sensation upon instillation. - Transient blurred vision lasting a few minutes. - Mild eye irritation or redness. - Temporary increase in tearing. - Mild headache in some users.

Serious or Rare Side Effects: - Severe allergic reaction such as anaphylaxis. - Significant increase in intra‑ocular pressure. - Prolonged vasoconstriction leading to ocular ischemia. - Corneal ulceration or epithelial damage. - Persistent eye pain or vision loss.

Before using Melet, consider the following safety measures. - Hypersensitivity: avoid if you have known allergy to pheniramine, tetryzoline or any excipient. - Glaucoma: use with caution in patients with narrow‑angle glaucoma. - Duration: do not exceed the recommended treatment period (typically 3‑5 days) to prevent rebound hyperemia. - Contact lenses: avoid wearing lenses during treatment and remove them before instillation. - Pediatric use: monitor children closely for systemic absorption signs. - Store at room temperature: keep in the original container, protect from light and moisture.

Melet may interact with other medicines; review the following.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Other ocular vasoconstrictors: may cause excessive vasoconstriction and ischemia. - Systemic alpha‑adrenergic agonists: additive blood‑pressure effects.

Moderate Interactions (Monitor Closely): - Concurrent topical ocular medications: possible reduced efficacy or irritation. - Contact lens solutions: may affect drug stability; rinse lenses before use. - Systemic antihistamines: potential additive sedation or anticholinergic load.